In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, metabolic surgery is associated with a lower risk for progression of kidney ...

EGFR is a protein on the surface of cells ... Your doctor can tell you what drug is available for you. You have treatment through a thin short tube (a cannula) that goes into a vein in your arm each ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

Each stage of this condition affects your kidneys a bit differently.There are five general stages of chronic kidney diseases ...

In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...

British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...

Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from ...

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...